Molecular serum signature of treatment resistant depression by Ruland, T et al.
  1 
 
 
Molecular serum signature of treatment resistant depression 
 
Tillmann Ruland M.D. 1,3*#, Man K Chan Ph.D.3*, Pawel Stocki Ph.D.3,  
Laura Grosse MSc. 1,2, Matthias Rothermundt M.D.1, Jason D Cooper Ph.D.3,  





1 Mood and Anxiety Disorders Research Unit, Department of Psychiatry and Psychotherapy, 
University of Muenster, Germany 
2Radiology Morphological Solutions, Rotterdam, The Netherlands 




* Both authors contributed equally to this work and should be considered shared first authors. 
  






Conflict of Interest 
Prof. Bahn is a director of Psynova Neurotech Ltd. Dr. Cooper is a consultant for Psynova 




This study was supported by EU-FP7-HEALTH-F2-2008-222963 “MOODINFLAME” and 
by EU-FP7-PEOPLE-2009-IAPP “PSYCH-AID”. These supporters had no further role in 
study design, in the collection, analysis and interpretation of data, in the writing of the 
report, and in the decision to submit the paper for publication.  
 
Drs Chan, Cooper and Prof. Bahn were also supported by grants from the Stanley 










A substantial number of patients suffering from major depressive disorder (MDD) do 
not respond to multiple trials of antidepressants, develop a chronic course of disease 
and become treatment resistant. Most of the studies investigating molecular changes in 
treatment resistant depression (TRD) have only examined a limited number of 
molecules and genes. Consequently, biomarkers associated with TRD are still lacking. 
 
Objectives 
To use recently advanced high-throughput proteomic platforms to identify peripheral 
biomarkers of TRD defined by two staging models, the Thase and Rush staging model 
(TRM) and the Maudsley Staging Model (MSM). 
 
Methods 
Serum collected from an inpatient cohort of 65 individuals suffering from MDD was 
analysed using two different mass spectrometric-based platforms, label-free liquid 
chromatography mass spectrometry (LC-MSE) and selective reaction monitoring (SRM), 
as well as a multiplex bead based assay. 
 
Results  
In the LC-MSE analysis proteins involved in acute phase response, complement 
activation and coagulation were significantly different between the staging groups in 
both models. In the multiplex bead based assay analysis TNF- levels (log(odds)=-4.95, 
p=0.045) were significantly different in the TRM comparison.  
Using SRM significant changes of three apolipoproteins A-I (=0.029, p=0.035), M (=-




Overall, our findings suggest that proteins, which are involved in immune and 
complement activation, may represent potential biomarkers that could be used by 
clinicians to identify high-risk patients. Nevertheless, given that the molecular changes 
between the staging groups were subtle, the results need to be interpreted cautiously.  
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INTRODUCTION 
 
The goal of treatment in major depressive disorder (MDD) is complete remission (Keller 
2003). Especially in the treatment of severely ill patients, antidepressant 
pharmacotherapy is one of the key strategies. However, after the initial trial of 
antidepressant treatment with selective serotonin reuptake inhibitors (SSRI) remission 
can only be achieved in 30 % of patients (Rush et al. 2006). Furthermore, a substantial 
number of patients do not respond to multiple trials of antidepressants and develop a 
chronic course of disease and become treatment resistant. Chronically depressed 
patients have a significant quality-of-life impairment, and a chronic course of disease is 
associated with a high socioeconomic burden (Rapaport et al. 2005). In order to assess 
resistant patients during the course of antidepressant treatment, different staging 
models have been proposed. These models vary considerably in definition and 
measurement of treatment resistant depression (TRD) (Fava 2003; Ruhé et al. 2012; 
McIntyre et al. 2014; Trevino et al. 2014). In addition, none of the existing models are 
routinely used by clinicians.  
 
Initially, Thase and Rush introduced a simple staging system for staging antidepressant 
resistance, the Thase and Rush Model (TRM), aimed at clinical psychiatrists managing 
non-responders (Thase and Rush 1997). The model consists of five stages usually 
beginning with a SSRI as first line intervention. The model has been used and reviewed 
extensively (Fava 2003; Nemeroff 2007; Ruhé et al. 2012). Another approach, the 
Maudsley Staging Model (MSM), which was proposed by Fekadu and colleagues (2009), 
attempted to overcome some disadvantages of the hierarchical Thase and Rush model, 
for example, by incorporating electroconvulsive therapy (ECT) as a non-hierarchical 
item (Fekadu et al. 2009). Furthermore, the authors tried to take into account both 
severity of disease and duration of illness (see Supplementary Figure 3).  
 
Other staging models such as the European Staging Model or the Massachusetts General 
Hospital Staging Model were not analysed in the present study. These models propose a 
minimum trial duration of 6 weeks, whereas Thase and Rush originally proposed a 4-
week trial duration as minimum trial length. The national and international guidelines 
recommend treatment modification after 4 weeks of treatment without response 
(NCCMH 2010; Deutsche Gesellschaft für Psychiatrie 2015). Therefore the adequate trial 
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length for a treatment trial without response was considered to be 4 weeks in our study. 
Furthermore, compared to the European Staging Model and the Massachusetts General 
Hospital Staging Model only the MSM includes both duration of illness and severity of 
depression (Ruhé et al. 2012).   
 
In the absence of biomarkers, both staging models addressed treatment resistant 
depression solely on the basis of clinical information. In order to sharpen our diagnostic 
assessment and to individually target our treatment strategies, there is an unmet need 
for valid blood-based biomarkers (Chan et al. 2014; Niculescu et al. 2015; Bahn and 
Chan 2015). 
 
Several studies have investigated molecules and genes associated with treatment 
response as well as TRD. Catechol-O-methyltransferase (COMT), brain-derived 
neurotrophic factor (BDNF) and the serotonin transporter (SLC6A4) gene 
polymorphisms have been investigated and may be associated with TRD and treatment 
response (Baune et al. 2008; Schosser et al. 2012). However, analysis of other 
candidates, for example cyclic adenosine monophosphate response element binding 
(CREB1) or dystrobrevin binding protein 1 (DTNBP1) gene, have not shown significant 
association with TRD (Schosser et al. 2012). Furthermore, a recently published large 
genome wide association study investigating genetic variation that may contribute to 
response to SSRI treatment has failed to show any significance at the genome-wide level 
(Biernacka et al. 2015). 
 
Cytokines and other proteins involved in inflammation such as Interleukin 6 (IL-6) and 
tumor necrosis factor (TNF) may be implicated in the response to treatment with 
antidepressants and the development of TRD (Lanquillon et al. 2000; O’Brien et al. 2007; 
Powell et al. 2013). A possible role of TNF in TRD has even led to clinical trials 
investigating the effect of TNF-alpha antagonists such as infliximab as a monotherapy or 
an add on medication in patients suffering from TRD (Raison et al. 2013; Schmidt et al. 
2014). In summary, until now molecular markers enhancing clinical staging or a blood 
test for response prediction or the identification of patients at high-risk of developing 
TRD are lacking. 
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Apart from the above-mentioned methods, high throughput proteomic techniques such 
as mass spectrometry may offer an alternative to discover blood-based protein 
biomarkers for TRD and treatment response (Chan et al. 2014). Moreover, a recently 
developed mass spectrometric analysis method, which makes use of triple quadrupole 
mass spectrometry, known as selective reaction monitoring (SRM) provides a new tool 
for the quantitative and highly specific detection of pre-selected analytes in complex 
biological samples such as human serum (Lange et al. 2008; Picotti and Aebersold 
2012). With this in mind and to extend the previous work on TRD biomarkers, we set 
out to identify serum biomarkers of TRD using different high throughput proteomic 
platforms. We hypothesized that molecular changes would be detectable across the 
different staging groups and tested this hypothesis by comparing two clinical models of 
treatment resistant depression, the TRM and the MSM, and using an inpatient cohort of 
65 individuals suffering from TRD.  
 
 
MATERIALS AND METHODS 
 
Study participants and sample collection 
This study was approved by the ethics committee of the medical association Westphalia-
Lippe, Germany (reference 2009-019-f-S). After study procedures had been fully 
explained, subjects provided written informed consent. 
 
Sixty-five patients with detailed clinical information were selected from a cohort 
recruited for the EU funded MoodInflame project aimed at early diagnosis, treatment 
and prevention of mood disorders targeting the activated inflammatory response 
system (reference: 222963) (for more information see http://moodinflame.eu). All 
patients were MDD inpatients from three different centres, which were diagnosed with a 
major depressive disorder and were taking antidepressant medication at the time of 
sample collection. Patients were screened and included at any time during their in-
hospital treatment. All patients met the Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria for MDD and clinical tests 
including administration of the Inventory of Depressive Symptomatology (IDS-C30) 
assessment were performed by psychiatrists under good clinical practice-compliance to 
minimise variability at inclusion. All patients were symptomatic at inclusion (ICD-C30 
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>12). MDD patients with other psychiatric co-morbidities were identified and screened 
for personal or family history of neuropsychiatric disorders using M.I.N.I. (German 
Version 5.0.0). Remission was defined as an IDS-C of ≤ 11 at discharge and partial 
remission  defined as IDS-C of ≥ 11 at discharge (Trivedi et al. 2004; Huijbers et al. 
2012). 
 
Staging of patients 
All patients were staged using the Thase and Rush Model (TRM) as well as Maudsley 
Staging Model (MSM). For the TRM, patients were strictly staged according to definitions 
of the stages in the original publication by an experienced clinician (see Supplementary 
Figure 1) (Thase and Rush 1997). An adequate treatment trial was defined as a period of 
at least four weeks with a moderate dose in line with national guidelines. Only clinical 
information concerning the current episode was used for the TRM and MSM. This 
included a period of eight weeks before admission for which reliable data of medication 
compliance could be collected for every patient.  MSM stages were assigned based on the 
total score meaning mild (scores = 3-6), moderate (scores = 7– 10) and severe (scores = 
11–15) treatment resistance (see Supplementary Figure 2) (Fekadu et al. 2009). In 
general, medication only received a score if it was given at adequate dose for at least six 
weeks. Therefore some patients treated with a tricyclic antidepressants (TCA) or 
electroconvulsive therapy (ECT) at the time of blood collection did not receive a score 
because trial length of the TCA or previous antidepressants were not sufficient for 
classification purposes.  
 
Since only one patient reached stage III resistance with a score of 11, the patient was 
included in the group of patients with stage II resistance (not being an outlier in 
statistical analysis). Important patient demographic and clinical characteristics such as 
gender, age, BMI, smoking alcohol consumption, chronic illness, family psychiatric 
disorder, depression severity (IDS-C) and use of non-psychiatric medication as well as 
psychiatric comorbidities were compared for both models in order to detect significant 
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Liquid chromatography coupled tandem mass spectrometry (LC-MSE ) analysis 
Serum samples were randomized and quality controls were added, before depleting of 
the most abundant proteins using a MARS14 (Agilent, USA) on a ÄKTA™ purifier UPC 10 
chromatography system (GE Healthcare, UK) as described previously (Jaros et al. 2013).  
 
A tryptic digest was performed after depletion and the samples were stored at -80 °C 
until LC-MSE analysis was performed. Using a Waters quadrupole time of flight (QTof) 
Premier mass spectrometer LC-MSE analysis was carried out by running every sample in 
triplicate, as described by Levin et al. After ProteinLync Global Server v.2.5. (Waters 
Corporation) and Rosetta Inpharmatics Biosoftware Elucidator v.3.3 (USA) data 
processing protein identification was performed as described previously (Stelzhammer 
et al. 2014). 
 
Selective reaction monitoring (SRM) mass spectrometry 
Samples were analysed by using a targeted SRM mass spectrometry approach on a 
predetermined set of peptides as described previously (Lange et al. 2008; Gottschalk et 
al. 2014). Briefly a Xevo TQ-S mass spectrometer (Waters Corporation) was coupled 
online through a New Objective nanoESI emitter (7cm length, 10mm tip; New Objective) 
to a nanoAcquity nano-ultra-performance liquid chromatography system (Waters 
Corporation). Peptide selection was done for candidate proteins identified previously by 
our lab and others (see Supplementary Table 1) (Penninx et al. 2003; Hummel et al. 
2011; Stelzhammer et al. 2014). For each target peptide, a heavy isotope-labeled 
internal standard (JPT Peptide Technologies GmbH) was spiked in the peptide mixture 
for accurate quantification and identification. 
 
Transitions were calculated and selected using Skyline version v2.5 (MacLean et al. 
2010). Each transition corresponded to singly charged y-ions from doubly- or triply-
charged precursor ions in the range of 350–1250Da. Method refinement was performed 
on quality control samples in order to select for the peptides with the maximal 
intensities and highest spectral library similarity (dotp > 0.9). A further development 
step of analyzing heavy-label spiked quality control samples in scheduled SRM mode 
was used to confirm identity via co-elution, extract the optimal fragment ions for SRM 
analysis, obtain accurate peptide retention times, and optimize collision energy and 
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cone voltage for the quantification run applying Skyline software (MacCoss Lab 
Software; MacLean et al., 2010).  
 
Multiplex bead based immunoassay 
High Sensitivity Hu Cytokine-T cell (MAGPX10223002) from Millipore was used as 
described in the manufacturers protocol. In summary, samples were thawed and 
antibody-immobilized beads were prepared. After preparing standards and buffers, the 
plate was prepared by washing it with a wash buffer. Samples, Standards and Beads 
were added to the appropriate wells and incubated overnight at 4°C. Contents were then 
removed and detection antibodies added. Following a 1 hour incubation at room 
temperature (RT) Streptavidin-Phycoerythrin was added and incubated for another 30 
minutes at RT. Finally drive fluid was added and the plate was run on a Luminex MagPix 





All statistical analyses were performed in R (http://www.R-project.org/) (R 
Development Core Team 2013). 
 
LC-MSE  and SRM data analysis 
The processed and normalised LC-MSE data was log transformed to stabilize variance 
and quality controls (QC) were assessed. Peptides with over 30% missing values and 
missed cleavage were excluded. Sample outliers were examined using principal 
components analysis (PCA) (Beniger et al. 1980) and through inspection of quantile-
quantile (Q-Q) plots.  
 
The SRM data was pre-processed using the R package MSstats (Clough et al. 2012). The 
data were log2 transformed and quantile normalisation was applied to remove 
systematic bias between MS runs. The resulting profile, QC and condition plots were 
carefully inspected to identify potential sources of variation for each protein, evaluate 
any systematic bias between MS runs and assess the variability of each condition per 
protein, respectively. Transitions with over 30% missing values were excluded. Sample 
outliers were examined as described above.  
  10 
For both the LC-MSE and SRM data, protein-level quantification and testing for 
differential abundance between the staging groups were performed using the random 
intercept linear mixed-effects model, as implemented in the R package nlme (Pinheiro 
et al. 2009). Random intercepts for subjects nested within recruitment centres were 
specified for each model to account for hierarchical structure of the data. The 
confounding effects of patient demographic characteristics such as age, BMI, gender, 
smoking status, alcohol use and chronic illnesses were accounted for in each model 
(fixed effects). False discovery rate was controlled according to Benjamini and 
Hochberg (Benjamini and Hochberg 1995). 
 
Multiplex bead-based immunoassay data analysis 
Immunoassay data were pre-processed to remove analytes with greater than 30 % 
missing values. Missing values are defined as analytes with measurement values below 
or above the detection limits. The resulting data were log10 transformed. Logistic 
regression was applied with staging status as the outcome and analyte as the predictor 
variables. The demographic variables listed above were made available for forward and 
backward stepwise selection (Hastie, T.J. Pregibon, D. 1992), with selection based upon 
Bayesian Information Criteria (BIC) (Schwarz 1978).   
 
 
RESULTS   
 
Demographic and clinical variables for the staging groups in both models were 
compared (Table 1). For the TRM, no significant differences existed across all covariates 
including age, gender, BMI, smoking and depression severity. For the MSM only 
depression severity was significantly different between stage I (mean = 30.53, standard 
deviation = ±8.15) and stage II (mean = 41.72, standard deviation ±9.50), which was due 
to depression severity being an item of the model itself (see Supplement Figure 2).  
 
Using logistic regression, both models showed no significant predictive capability to 
discriminate between the group of patients achieving remission and the patients with 
only partial remission at discharge (for TRM log(odds)=-0.89, p=0.119; for MSM 
log(odds)=-1.16, p=0.067). Although, the predictive validity of the MSM has been shown 
previously, this could not be replicated in our study.  
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Using a non-hypothesis driven label-free LC-MSE approach, a number of proteins were 
identified to be significantly different between the staging groups in both models (Table 
2, Supplementary Table 2 for the list of all detected proteins). Based on a Gene Ontology 
(GO) term analysis these proteins were mainly involved in the biological process of 
acute phase response, complement activation, coagulation and oxygen transport (The 
Gene Ontology Consortium 2000; The Gene Ontology Consortium 2015). For the TRM 
stage comparison, a total of eight proteins could be detected as significantly different: 
Serum amyloid P-component (=0.035, p=0.008 FC=1.08), Ficolin-3 (=0.033, 
p=0.021FC= 1.08), C4b-binding protein beta chain (=0.053, p=0.023, FC=1.13), C4b-
binding protein alpha chain (=0.030, p=0.024, FC=1.07), Complement C1q 
subcomponent subunit C (=0.026, p=0.037, FC=1.06), Histidine-rich glycoprotein (=-
0.053, p=0.024, FC=0.88), Nuclear factor of activated T-cells (=0.047, p=0.027, 
FC=1.11) and Beta-Ala-His dipeptidase (=-0.053, p=0.049, FC=0.88). Interestingly, 
almost all of the proteins were involved in acute phase response, complement activation 
and coagulation.  
 
For the MSM stage comparison, ten proteins were significantly changed: Heparin 
cofactor 2 (=-0.023, p=0.004, FC=0.95), Plasma serine protease inhibitor (=0.034, 
p=0.012, FC=1.08), Antithrombin-III (=0.039, p=0.023, FC=1.09), Interleukin-1 
receptor accessory protein (=0.067, p=0.026, FC=1.17), Complement factor D (=0.059, 
p=0.037, FC=1.15), Hemoglobin subunit alpha (=-0.400, p=0.008, FC=0.40), 
Hemoglobin subunit beta (=-0.227, p=0.017, FC=0.59), Putative postmeiotic 
segregation increased 2-like protein 11 (=0.099, p=0.004, FC=1.26), Calcium-binding 
protein 5 (=-0.068, p=0.023, FC=0.85), Cytosolic beta-glucosidase (=0.051, p=0.039, 
FC= 1.12). 
 
On a protein-level, no overlap could be detected between MSM and TRM stage 
comparisons. However, the top GO terms were similar in both comparisons. Except for 
the proteins Hemoglobin subunit alpha and beta involved in oxygen transport, fold 
changes were mainly subtle. Testing for multiple corrections using the Benjamini 
Hochberg method yielded no statistically significant results (adjusted p-value >0.05).  
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A multiplex bead based assay was used to further elucidate possible changes in 
inflammatory proteins previously implicated in depression (Penninx et al. 2003; 
Kaestner et al. 2005; Simon et al. 2008). A total of 7 analytes were included in the 
analysis (IFN-, IL12p70, IL-4, IL-6, IL-7, IL-8, TNF-). In the TRM comparison, 
significant differences in TNF- levels between the groups could be detected 
(log(odds)=-4.95, p=0.045). There were no significant differences for the MSM stage 
comparison (Table 3). In addition, no significant correlation could be shown between 
the MSM score and the analytes (data not shown). 
 
Furthermore, another mass spectrometry method, Selective Reaction Monitoring (SRM), 
was used to analyse the samples. For the SRM assay a panel of apolipoproteins and 
inflammation-related proteins implicated in major depression was selected (see 
Supplementary Table 1). These analytes were chosen based on previous findings by our 
group (Stelzhammer et al. 2014; Bot et al. 2015) and others (Hummel et al., 2011;). In 
addition, the most significant proteins identified by label-free LC-MSE were selected for 
further validation. Significant changes could only be detected for the TRM stage 
comparison (Table 4). Three apolipoproteins A-I (=0.029, p=0.035, FC=1.02), M (=-
0.017, p=0.009, FC=0.99) and F (=-0.031, p=0.024, FC=0.98) as well as alpha-1-
antichymotrypsin (=0.025, p=0.032, FC=1.02) were found to be changed. However, 
changes of Ficolin-3, Complement C1q subcomponent subunit C and Histidine-rich 
glycoprotein, which were significantly changed in the label-free LC-MSE experiment, 





The objective of this study was to evaluate possible molecular phenotypes underlying 
treatment resistant depression based on two clinical staging methods using proteomics. 
The use of proteomics for discovering blood-based biomarkers in different medical 
fields has progressed substantially over the last years (Hanash et al. 2008; Shao et al. 
2015). New analysis methods such as SRM have been developed recently and offer novel 
ways of analysing a predetermined set of proteins in a complex mixture like human 
serum across multiple samples (Picotti and Aebersold 2012). To our knowledge, this is 
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the first study using SRM to detect pre-selected analytes in a MDD cohort suffering from 
TRD.  
 
While group comparison in the TRM showed significantly changed proteins in all three 
assays, only the LC-MSE analysis showed significant changes in the MSM. GO Term 
analysis revealed that the identified proteins were mainly involved in complement 
activation and coagulation. Upregulation of the closely interacting proteins serum 
amyloid P component and the C4b-binding protein in the Stage II TRM group might 
suggest an altered regulation of the complement system in more severely affected 
patients (García de Frutos and Dahlbäck 1994). Interestingly, changes of TNF alpha 
levels in the TRM model using a multiplex bead based immunoassay corresponded to 
results of previous studies, which showed a relationship between response and TNF 
alpha level decrease (Lanquillon et al. 2000; Strawbridge et al. 2015). SRM analysis 
revealed three apolipoproteins being changed in the TRM group comparison. A possible 
role of apolipoprotein changes during treatment of MDD has been suggested by previous 
studies (Sadeghi et al. 2011; Hummel et al. 2011).  
 
A possible role of inflammation in the pathogenesis of MDD has been studied extensively 
in patients as well as in animal models of depression (Dantzer et al. 2008; Iwata et al. 
2013). Furthermore, levels of inflammation related genes predict lack of response to 
antidepressants (Cattaneo et al. 2013). A recent meta-analysis revealed an association of 
IL-1β and IL-6 levels with suicidality (Black and Miller 2015). Anti-inflammatory drugs 
have also been found to antagonize the therapeutic efficacy of antidepressant agents  
(Warner-Schmidt et al. 2011; Miller and Raison 2016). Therefore, further studies are 
needed to elucidate a potential relationship between inflammatory activation and 
different stages of TRD.  
 
Some limitations of the study design have to be considered. The sample size for this pilot 
study was small and an independent validation cohort was not available, hence larger 
prospective studies are warranted. Furthermore, the cohort of patients used in this 
study was not specifically recruited to assess all stages of treatment resistant depression 
as defined by the two staging methods. Therefore, patients with a very high number of 
unsuccessful treatment trials (five or more) could be underrepresented. Since the cohort 
did not include outpatients, no control group of responders to a first treatment trial was 
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available. In addition, the TRM did not account for the use of augmentation strategies. 
Since medication had to be taken for a period of six weeks in MSM, only 16 patients 
received augmentation therapy long enough to score >0. Robust clinical data offering 
information about response time to an augmentation strategy in TRD is not available 
and needs further evaluation in specifically designed clinical trials (Keller 2005; 
Carvalho et al. 2007). Other staging models have been designed, which were not 
analysed in this study, therefore leaving the question open if different molecular 
phenotypes underlying the staging in these models (Ruhé et al. 2012).  
 
In conclusion, our findings suggest that proteins involved in complement system 
activation, inflammatory response, and lipid transport could be interesting candidates to 
stratify TRD at the molecular level. However, given that the molecular changes between 
the staging groups were subtle, the results have to be interpreted cautiously. With 
regard to the limitations of study, this pilot data shows the need for optimization of the 
clinical staging models by conducting prospective clinical trials. Advances in proteomics 
technologies in terms of analytical sensitivity and resolution as well as cost-
effectiveness now allow for improved targeted molecular measurements. Such advances 
may offer a wider range of biomarkers potentially capable of allowing for stratification 
of molecular phenotypes underlying treatment resistant depression.   
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TABLE 1 
 
Thase and Rush staging model (TRM) Maudsley Staging Model (MSM) 
Stage I Stage II P-value Stage I Stage II P-value 
n 36 29 NA 41 24 NA 
Gender (M/F)F (15/21) (18/11) 0.136 (23/18) (10/14) 0.310 
AgeW 39.69 (±12.60) 40.30 (±11.12) 0.979 41.43 ( ±11.74) 36.71 ( ±11.79) 0.138 
BMIW 27.83 (±5.88) 27.07 (±4.96) 0.853 27.36 ( ±5.98) 28.25 ( ±4.81) 0.215 
Smoking  (yes/no)F (13/23) (9/20) 0.794 (14/27) (8/16) 1.000 
Alcohol (yes/no)F (30/15) (16/20) 0.324 (18/23) (13/11) 0.452 
Chronic illness 
(yes/no)F 
(6/30) (9/20) 0.238 (9/32) (6/18) 0.770 
Family psychiatric 
disorder (yes/no/NA)F 
(25/7/4) (17/9/3) 0.558 (29/10/2) (13/6/5) 0.129 
Depression severity 
(IDS-C30)W 
33.53 (±9.56) 33.18 (±9.56) 0.372 30.53 (±8.15) 41.72 (±9.50) 2.0E-06 
Time (weeks) between 
admission & discharge 
9.84 (±5.95) 10.79 (±7.60) 0.50 9.45 (±4.90) 11.65 (±8.93) 0.51 
Use of non-psychiatric 
medication (yes/no)F 
(11/25) (11/18) 0.603 (11/30) (11/13) 0.174 
Psychiatric 
Comorbidities (yes/no)F  
(12/24) (10/19) 1.000 (14/27) (8/16) 1.000 
Remission/Partial 
RemissionF 
(14/22) (6/23) NA* (16/25) (4/20) NA* 
F = Fisher’s exact test; W = Wilcoxon test; TRM = Thase and Rush staging model; MSM = Maudsley Staging 
Model; n = sample size; BMI = Body Mass Index; IDS-C30 = Inventory of Depressive Symptomatology IDS-
C30 
 
Legend to table 1: Patient demographic and clinical characteristics. The staging groups are shown 
separately for TRM and MSM stages (mean ± sd for continuous variables) significance level at p < 
0.05. * Using logistic regression, both models showed no significant predictive capability (see 
results section for details). 
 
TABLE 2 
TRM      





P-value FC (TRM II /TRM I) 
Acute phase response Serum amyloid P-component  0.035 0.013 0.008 1.08 
Complement 
activitaion 
Ficolin-3 0.033 0.014 0.021 1.08 
 
C4b-binding protein beta chain 0.053 0.023 0.023 1.13 
 
C4b-binding protein alpha chain 0.030 0.013 0.024 1.07 
 
Complement C1q subcomponent subunit C 0.026 0.012 0.037 1.06 
Blood coagulation Histidine-rich glycoprotein  -0.053 0.023 0.024 0.88 
Immune response  Nuclear factor of activated T-cells 0.047 0.021 0.027 1.11 
Dipetidase  Beta-Ala-His dipeptidase  -0.053 0.026 0.049 0.88 
      
MRM       





P-value FC (MSM II/MSM I) 
Blood coagulation Heparin cofactor 2 -0.023 0.008 0.004 0.95 
 
Plasma serine protease inhibitor  0.034 0.013 0.012 1.08 
 
Antithrombin-III  0.039 0.017 0.023 1.09 
Immune response Interleukin-1 receptor accessory protein 0.067 0.029 0.026 1.17 
Complement 
activitation 
Complement factor D  0.059 0.028 0.037 1.15 
Oxygen transport Hemoglobin subunit alpha  -0.400 0.145 0.008 0.40 
 
Hemoglobin subunit beta  -0.227 0.092 0.017 0.59 
Mismatch repair Putative postmeiotic segregation  0.099 0.033 0.004 1.26 
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increased 2-like protein 11  
Signal transduction Calcium-binding protein 5 -0.068 0.029 0.023 0.85 
Glycosidase  Cytosolic beta-glucosidase  0.051 0.024 0.039 1.12 
TRM = Thase and Rush staging model; MSM = Maudsley Staging Model;  = Regression Coefficient 
Estimates; Std. Error = Regression standard error; FC = Fold change. 
 
Legend to table 2: Results of the non-hypothesis driven label-free LC-MSE approach. (FC= fold 
change) Go Terms shown for the biological process in which the identified protein is involved. 




   Protein Log (odds) Std. Error P-value 
IFN- 0.58 1.01 0.568 
IL-10 0.08 0.51 0.870 
IL-12p70 -0.61 0.68 0.365 
IL-2 -0.27 0.63 0.672 
IL-4 -0.03 0.47 0.957 
IL-6 -0.25 0.71 0.723 
IL-7 0.64 1.39 0.644 
IL-8 0.43 0.98 0.664 
TNF- -4.95 2.47 0.045 
    MSM 
   Protein  Log (odds) Std. Error P-value 
IFN- 1.24 1.59 0.249 
IL-10 -0.24 0.64 0.646 
IL-12p70 0.41 0.88 0.566 
IL-2 -0.01 0.80 0.987 
IL-4 -0.50 0.64 0.318 
IL-6 0.32 0.85 0.669 
IL-7 0.22 1.68 0.876 
IL-8 -0.81 1.26 0.445 
TNF- -2.92 2.62 0.168 
TRM = Thase and Rush staging model; MSM = Maudsley Staging Model; Std. Error = Regression standard 
error; IFN- = Interferon-gamma; IL12p70 = Interleukin 12p70; IL-2 = Interleukin 2; IL-6 = Interleukin 6, 
IL-7 = Interleukin 7; IL-8 = Interleukin 8; TNF- = tumor necrosis factor alpha 
 
Legend table 3: Results of multiplex bead based assay. In TRM group comparison a significant 
difference was found for TNF-. No significant differences could be detected for MSM. Significance 

















Apolipoprotein M -0.017 0.006 0.009 0.99 0.004 0.008 0.576 1.00 
Apolipoprotein F -0.031 0.013 0.024 0.98 -0.008 0.016 0.630 1.00 
Apolipoprotein A-I 0.029 0.013 0.035 1.02 -0.003 0.017 0.557 1.00 
Alpha-1-antichymotrypsin 0.025 0.011 0.032 1.02 0.008 0.014 0.557 1.01 
TRM = Thase and Rush staging model; MSM = Maudsley Staging Model;  = Regression Coefficient 
Estimates; Std. Error = Regression standard error; FC = Fold change 
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Legend to table 4: Results of Multiple Reaction Monitoring analysis. No significant differences 
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